True Leaf Medicine International Inc.
True Leaf Medicine International Inc.
- ISIN: CA89785C1077
- Land: .
Nachricht vom 20.04.2017 | 09:04
True Leaf Close to Completing Process for Marijuana License
DGAP-News: True Leaf Medicine International Inc. / Key word(s): Miscellaneous
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2017) - True Leaf Medicine Inc. (CSE: MJ) (FSE: TLA) ('True Leaf'), a division of True Leaf Medicine International Ltd., is two steps away from completing the process to acquire a license to produce and grow marijuana in Canada. True Leaf is now proceeding to stage five of the process, the 'Review', two years after submitting its application to Health Canada.
True Leaf is one out of over 100 companies that currently have applications in the review stage for a license to produce marijuana, out of a total of 1,630 applications received by Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Today, there are just 43 licensed producers in Canada.
True Leaf will be working with industry experts to ensure the company meets or exceeds the operating, facility, security, and reporting procedures during this next step in the ACMPR application process. This will allow True Leaf to proceed to a 'pre-license inspection' stage in the coming months.
This development comes as the Federal Government tabled the Cannabis Act last week, which will lead to the regulation and control of marijuana used for recreational purposes. True Leaf is now working to ensure the company will comply with regulations directed by Health Canada under this new legislation, to allow True Leaf to participate in all aspects of marijuana production granted to license producers.
'The Cannabis Act regulations appear to closely follow the recommendations of the Task Force on Cannabis Legalization and Regulation and also align with our own recommendations that we released last year,' said True Leaf Chair Mike Harcourt. 'We feel the regulations will ultimately provide a foundation for the safe and secure production of cannabis within a legal framework that focuses on responsible use.'
As True Leaf goes through the ACMPR licensing process, the company has increased value for shareholders by creating its pet division, True Leaf Pet. The company has been marketing hemp-based supplements for pets since 2015, which are now distributed throughout North America and Europe. True Leaf's work in the pet industry is a valuable experience that can be leveraged to build-out the company's future health and wellness line of high-CBD cannabis products for humans when it becomes a licensed producer.
'It has been a long journey, but our mission remains the same. We intend to supply customers interested in the healing power of cannabis, to improve the quality of life of Canadians,' said True Leaf CEO Darcy Bomford.
About True Leaf:
True Leaf Medicine International Ltd., through its wholly-owned subsidiary 'True Leaf Pet', has entered the $104.9 billion global pet care industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Canada, the United States and Europe. The company has also filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer through its 'True Leaf Medicine' subsidiary. It has passed through the preliminary and enhanced screening process of Health Canada's review and is currently awaiting security clearance and 'pre-licensing inspection' approval.
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/26237
|Company:||True Leaf Medicine International Inc.|
|End of News||DGAP News Service|
GBC im Fokus
23. MKK – Münchner Kapitalmarkt Konferenz
Für: Institutionelle Investoren & Presse
Wann: 26. & 27. April 2017, 9 - 17 Uhr
Wo: The Charles Hotel - Rocco Forte Hotels, München
GBC im Fokus
Neovacs S.A.: Kursziel auf 3,30 € angehoben
In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.
Der AKTIONÄR News
25. April 16:29 Biotech-Sektor: Starke Biogen-Zahlen treiben an
25. April 16:15 Netflix erobert China durch die Hintertür – Aktie wieder auf ...
25. April 15:11 Innogy: Keine Panik!
25. April 13:44 Bußlers Geheimtipps: … jetzt erst einmal die Korrektur
News im Fokus
Continental startklar: Nächster Wachstumsschub durch innovative Antriebstechnologien
25. April 2017, 08:30
Q1 Results 2017
10. Mai 2017
Original-Research: Ludwig Beck AG (von Montega AG): Kaufen
25. April 2017